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Background: The new World Health Organization (WHO) classification system proposed
a cell lineage-based classification scheme for pituitary adenomas in which transcription
factors (TFs) play a major role as key classifiers. We aimed to evaluate clinical relevance of
the new classification system in a clinical setting.
Methods: TF staining was retrospectively performed for 153 clinically and histologically
well characterized pituitary adenomas. Then, 484 pituitary adenomas were prospectively
stained for TFs and then for relevant pituitary hormones. TF and hormone stain-based
diagnoses were compared, and differences in clinical manifestations were evaluated.
Results: The accuracies of antibodies for three TFs were successfully validated and had
an overall matching rate was 89.6%. We identified 50 (10.4%) cases with discrepancies
between TF and pituitary hormone stains. Gonadotroph adenomas lacking follicle-
stimulating hormone and luteinizing hormone stains account for most discrepancies.
Null cell adenomas may be more prevalent than reported and may be clinically more
aggressive than gonadotroph adenomas.
Conclusion: The new WHO classification is mostly well matched with the traditional
classification. However, until the new classification is further validated and interpreted in
the context of long-term clinical outcomes, routine histological examination should include
full slate of immunostains for pituitary hormones as well as TFs.
Keywords: immunohistochemistry, pituitary adenoma, pituitary hormone, transcription factor, WHO classificationSeptember 2021 | Volume 11 | Article 7392901
Hong et al. New WHO Classification for Pituitary AdenomasINTRODUCTION
Pituitary adenomas are neuroendocrine tumors in the anterior
pituitary gland. They are traditionally classified based on their
hormonal activity as non-functioning and endocrine-active
tumors. Histopathological examination is important to confirm
the diagnosis by validation of positive immunohistochemistry
(IHC) for relevant pituitary hormones. The fourth edition of the
World Health Organization (WHO) classification of endocrine
tumors was published in 2017 (1). One of the major changes in
the new scheme is the cell lineage-based classification of pituitary
adenomas characterized by lineage-specific transcription factors
(TFs). All pituitary adenomas are divided into the three following
lineages: lactotroph, somatotroph, and thyrotroph belong to
PIT-1 (pituitary-specific TF 1), corticotroph belongs to T-PIT
(pituitary cell-restricted factor), and gonadotroph belongs to
SF-1 (steroidogenic factor 1). Tumors negative for all three TFs
are considered as true null cell adenomas.
In September 2018, we started to provide pathological
diagnoses for all pituitary adenomas surgically removed in our
institution based on the new WHO classification system. Based
on our 2-year experience, we aimed to evaluate the clinical
relevance of new classification system and discrepancies
between pituitary hormone-based and TF-based diagnoses.MATERIALS AND METHODS
This study was conducted in accordance with the Declaration of
Helsinki and approved by the local Institutional Review Board.
The IHC antibodies used for TFs and pituitary hormones are
listed in Table 1. Every single sample was examined by twoFrontiers in Oncology | www.frontiersin.org 2experienced neuropathologists. The hormone-positivity was
described as focal/diffuse and weak/strong. For the stains for
TFs, roughly 5% of cutoff was adopted. We considered cases with
even very week stains for TFs in the nucleus as positive.
Retrospective Validation
Before September 2018, our routine pathological examination for
pituitary adenomas included IHC for all anterior pituitary
hormones: adrenocorticotropic hormone (ACTH), growth
hormone (GH), prolactin (PRL), thyroid-stimulating hormone
(TSH), luteinizing hormone (LH), and follicle-stimulating
hormone (FSH). We retrospectively selected 49 non-
functioning pituitary adenomas including 27 null cell tumors
and 22 gonadotroph adenomas. None of these patients presented
any symptoms suggesting hormonal excess. We then identified
104 endocrine-active pituitary adenomas: 36 GH-secreting
adenomas, 28 prolactinomas, 21 TSH-secreting adenomas, and
19 ACTH-secreting adenomas. For all 104 patients with
endocrine-active pituitary adenomas, their hormonal excess
was well matched with laboratory tests and clinical symptoms.
Acromegaly was defined when the nadir serum GH level after an
75g oral glucose tolerance test was less than 1.0 ng/mL with
elevation of serum insulin-like growth factor-1 adjusted for age
and sex. The diagnosis of Cushing’s disease was established on
the basis of clinical features and the results of biochemical tests
including 24 h urinary free cortisol excretion, low- and/or high-
dose dexamethasone suppression test. And bilateral inferior
petrosal sinus sampling was performed in all cases. The
diagnosis of TSH-secreting pituitary adenoma was made based
on serum TSH, free thyroxine, triiodothyronine levels together
with the radio of free alpha subunit and TSH, which was later





Antigen retrieval Antibody primary
Transcription factors




Nuclear Conventional BenchMark XT instrument, 32 minutes,
37°C
T-PIT Atlas Antibodies AMAb91409 1/1000 Dako, Omnis Nuclear Low pH, 30
minutes





1/400 Dako, Omnis Nuclear Low pH, 30
minutes
Omnis instrument, 20 minutes, 32°C
Pituitary hormones
GH DAKO, Agilent A0570 1/400 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°C
PRL DAKO, Agilent A0569 1/300 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°C
TSH DAKO, Agilent M3503 1/50 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°C
ACTH DAKO, Agilent M3501 1/200 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°C
LH DAKO, Agilent M3502 1/50 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°C
FSH DAKO, Agilent M3504 1/50 Ventana, BenchMark
XT
Cytoplasmic Not required BenchMark XT instrument, 32 minutes,
37°CSeptemACTH, adrenocorticotropic hormone; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; PIT-1, pituitary specific transcription factor 1; PRL, prolactin; SF-1,
steroidogenic factor 1; T-PIT, pituitary cell restricted factor; TSH, thyroid stimulating hormone.ber 2021 | Volume 11 | Article 739290
Hong et al. New WHO Classification for Pituitary Adenomassuppression test was performed when it was unclear whether the
patient had a TSH-secreting pituitary adenoma or a non-
functioning pituitary adenoma in the presence of secondary
hyperthyroidism. IHC of three TFs was then performed for
cell-lineage classification. The classifications based on pituitary
hormones and TFs were compared.
Prospective Validation
Since September 2018, the routine pathological examination
protocol for pituitary adenomas was updated based on the new
WHO classification (Figure 1). Informed consent was obtained
from enrolled patients. We first performed IHC for three TFs:
PIT-1, T-PIT, and SF-1. Then, IHC was performed for possibly
associated hormones based on the result of TF stains: GH, PRL,
and TSH for PIT-1 adenomas; only ACTH for T-PIT adenomas;
and LH and FSH for SF-1 adenomas. When the hormone stain
results were not matched to TF stains, the tests were repeated and
IHC was performed for all pituitary hormones. For all discordant
cases, IHC for TF stains and hormone stains were repeated to
confirm the results. Cases with incomplete study and with
pituitary apoplexy that prevented reliable IHC were excluded
from this study. A total of 484 patients who underwent surgical
resection for their pituitary adenomas by two neurosurgeons
from September 2018 to August 2020 were included in this
analysis. First, hormone and TF stains were compared to
determine whether they were well matched. For patients withFrontiers in Oncology | www.frontiersin.org 3concordant results, histological and clinical diagnoses were
compared with subgroup analysis of their tumor nature.Statistical Analysis
We performed t-tests and chi-square tests to identify statistically
significant differences. All analyses were performed using IBM
SPSS Statistics (version 20.0; IBM, Armonk, NY, USA), and P <
0.05 was considered statistically significant.RESULTS
Retrospective Validation
The results of our retrospective analysis are summarized in
Table 2. For 153 cases of pituitary adenomas previously
operated in our institution based on the traditional
classification scheme, we performed IHC for three TFs and
compared the findings. The results were consistent in 149
(97.4%) cases. We identified only five cases with discrepancies
between hormonal and TF stains. One patient with overt
Cushingoid features and positive ACTH stain was negative for
all TFs. There were four endocrine-inactive pituitary adenomas
with negative stains for all pituitary hormones; a positive stain
for T-PIT was observed in one patient and SF-1 in three patients.FIGURE 1 | Pathological examination protocol for pituitary adenomas based on the new WHO classification. First, immunostains of transcriptions factors (PIT-1,
T-PIT and SF-1) were performed for determination of cell lineage. And then, following stains were performed only for possibly associated hormones based on the
result of TF stains; GH, PRL and TSH for PIT-1 positive adenomas, only ACTH for T-PIT positive adenomas and LH, FSH for SF-1 positive adenomas. ACTH,
adrenocorticotropic hormone; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; PIT-1, pituitary specific transcription factor 1;
PRL, prolactin; SF-1, steroidogenic factor 1; T-PIT, pituitary cell restricted factor; TSH, thyroid stimulating hormone.September 2021 | Volume 11 | Article 739290
Hong et al. New WHO Classification for Pituitary AdenomasProspective Validation
The cohort included 303 endocrine-inactive tumors and 181
endocrine-active tumors including 86 GH-secreting pituitary
adenomas, 57 prolactinomas, 36 ACTH-secreting pituitary
adenomas, 2 TSH-secreting adenomas. While prolactinoma is
known to be the most common type of pituitary adenomas, the
prevalence of prolactinomas is possibly underestimated in our
surgical series because majority of them were treated with
dopamine agonists without pathological diagnosis. Also,
compared to other series in the literature, much more patientsFrontiers in Oncology | www.frontiersin.org 4with endocrine-inactive pituitary adenomas (62.6%) were
enrolled to our study.Comparison Between TF and Pituitary
Hormone Stains
First, we identified three unusual tumors that could not be
classified into any specific category. These tumors were
positive for multiple TFs; one Cushing’s disease patient had
positive IHC for T-PIT, and SF-1, and two acromegalic patients
had positive IHC for both PIT-1 and SF-1 (Figure 2). Complete
resection was done in all three cases, but one acromegalic patient
did not achieve endocrinological remission.
For the other 481 patients, we evaluated whether their TF stains
were well matched with their pituitary hormone stains (Figure 3
and Table 3). The most common subtype was PIT-1 positive
adenoma, and the overall matching rate was 89.6%. We identified
50 (10.4%) patients with pituitary adenomas whose pathological
examinations were discrepant between TF and pituitary hormone
stains. The majority of mismatched cases were gonadotroph
adenomas (43 patients, 86.0%) with stains positive for SF-1 but
negative for both FSH and LH. The second-most common tumor
type was null cell adenomas positive for ACTH stain (n=4). The
most common subtype of gonadotroph adenoma was FSH
positive, while LH-positive tumors were the least common. In
171 PIT-1 positive adenomas, the most prevalent subtype was
GH-positive tumors followed by prolactinoma. Tumors with
positive stains for two or more hormones were more prevalent
than single hormone-positive tumors (53.2% vs. 46.8%). PRL, GHFIGURE 2 | Three tumor cases with positive IHC for multiple transcriptions factors. In our prospective investigation on 484 pituitary adenomas, three unusual cases
were identified as their cell lineages were not clearly classified. They were 1 Cushing’s disease patient with positive IHC for T-PIT, and SF-1, and two acromegalic
patients with positive IHC for both PIT-1 and SF-1. In Patient 2, positive stains for PIT-1 and SF-1 were observed in the same cells. PIT-1, T-PIT and SF-1 X 100.
IHC, immunohistochemistry; PIT-1, pituitary specific transcription factor 1; SF-1, steroidogenic factor 1; T-PIT, pituitary cell restricted factor.TABLE 2 | Retrospective comparison of immunohistochemistry between












19 18 (94.7%) Negative for all TFs
Single PRL positive 28 28 (100%)
Single GH positive 36 36 (100%)




All negative 27 23 (85.2%) Positive for T-PIT in 1
and SF-1 in 3
Total 153 148 (96.7%)ACTH, adrenocorticotropic hormone; FSH, follicle stimulating hormone; GH, growth
hormone; LH, luteinizing hormone; PRL, prolactin; SF-1, steroidogenic factor 1; TF,
transcription factor; T-PIT, pituitary cell restricted factor; TSH, thyroid stimulating hormone.September 2021 | Volume 11 | Article 739290
Hong et al. New WHO Classification for Pituitary Adenomasand TSH stain were positive in 121 (70.8%), 107 (62.6%) and 40
(23.4%) PIT-1 positive adenomas, respectively.
Comparison Between Histological
Diagnosis and Clinical Diagnosis
For the 431 patients with concordant results between TF and
pituitary hormone stains, comparative analysis was performed
for their histological and clinical diagnoses (Table 4).
Among 177 endocrine-active tumors, 174 (98.3%) had
concordant clinical and histological diagnoses. When weFrontiers in Oncology | www.frontiersin.org 5compared 32 patients with endocrine-active corticotroph
adenoma (Cushing’s disease) with its counterpart (23 silent
corticotroph adenomas), we observed that tumors were much
larger in silent corticotroph adenoma patients than in Cushing’s
disease patients (25.3 mm vs. 12.4 mm, P<0.001). However, there
was no statistically significant difference between the incidence of
cavernous sinus invasion and total tumor removal. In the
comparison between patients with functioning PIT-1 adenomas
(GH-secreting adenoma, prolactinoma, and thyrotropinoma) and
silent PIT-1 adenoma patients, we failed to identify any of these.
A total of 254 endocrine-inactive tumors with no clinical or
laboratory evidence of hormonal excess were further analyzedFIGURE 3 | Comparison between immunohistochemical stain for transcription factors and pituitary hormones. The most common subtype was PIT-1 positive
adenomas. In 171 PIT-1 positive adenomas, the most prevalent subtype was a prolactinoma followed by GH-positive tumors. The most common subtype of
gonadotroph adenomas was a FSH-positive tumor and LH-positive tumors were the least common. Overall, 10.4% of cases showed discordance between TF stains
and pituitary hormone stains. The majority of mismatched cases were gonadotroph adenomas of which stains were positive for SF-1 but negative for both FSH and
LH. FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; PIT-1, pituitary specific transcription factor 1.TABLE 3 | Comparison between immunohistochemical stain for TFs and
pituitary hormones.










PIT-1 positive 171 1* 172 (35.8%)
T-PIT positive 55 1* 56 (11.6%)
SF-1 positive 1* 91 43* 135 (28.1%)
All negative 4* 114 118 (24.5%)
Total 171 60 92 158 481*Cases with discrepancy between TF and pituitary hormone stains.
ACTH, adrenocorticotropic hormone; FSH, follicle stimulating hormone; GH, growth
hormone; LH, luteinizing hormone; PIT-1, pituitary specific transcription factor 1; PRL,
prolactin; SF-1, steroidogenic factor 1; TF, transcription factor; T-PIT, pituitary cell
restricted factor; TSH, thyroid stimulating hormone.TABLE 4 | Comparison between clinical manifestations and histology for 431










Cushing’s disease *1 32 *1 34
Acromegaly 84 84
Prolactinoma 55 *2 57
TSHoma 2 2
Non-functioning adenoma *29 *23 91 111 254
Total 171 57 91 114 431September 2021 | Volume 11 | Article 7*Cases with discrepancy between clinical manifestations and histology.
PIT-1, pituitary specific transcription factor 1; SF-1, steroidogenic factor 1; TF, transcription
factor; T-PIT, pituitary cell restricted factor; TSH, thyroid stimulating hormone.39290
Hong et al. New WHO Classification for Pituitary Adenomas(Figure 4). In this group, there were more patients with true null
cell adenomas (n=111) that were not positive for TFs or pituitary
hormones than gonadotroph adenoma patients (n=91), followed
by 23 patients with silent corticotroph adenoma and 29 with
silent PIT-1 adenomas. Although tumor size did not differ, null
cell adenomas showed more frequent cavernous sinus invasion
than gonadotroph adenomas (P=0.043), which led to a difference
in the likelihood of total tumor removal (P=0.039). Tumors were
the smallest in patients with silent PIT-1 adenomas (P<0.001 vs.
null cell adenomas and gonadotroph adenomas, P=0.054 vs.
silent corticotroph adenomas). The incidence of cavernous
sinus invasion was highest for silent corticotroph adenoma
(P=0.032 vs. gonadotroph adenomas), which is a well-known
aggressive form of pituitary adenoma. Conversely, patients with
gonadotroph adenomas were less likely to have cavernous sinus
invasion. Among 29 patients with silent PIT-1 adenomas, 28
underwent total removal, which was a significantly higher
percentage than patients with null cell adenomas or silent
corticotroph adenomas.DISCUSSION
In recent decades, several TFs have been found to regulate cellular
differentiation of the adenohypophysis, and they are also essential
for differentiation and maturation of the neuroendocrine cells
from Rathke’s pouch (2, 3). As TFs determine hormone-specific
pituitary stem cell development, IHC for pituitary hormones and
cell-specific TFs enables classification of differentiated pituitary
adenomas based on pituitary cell lineage (4). Many studies have
shown that TF staining can be a major ancillary diagnostic tool for
more precise classification of pituitary adenomas (5–7).
Considering that immunostain findings for pituitary hormones
are often focal, very weak, or uncertain, TF staining may serve as a
critical determinant for histological diagnoses in such instances.
Based on these findings, the fourth edition of WHO classification
system proposed a cell lineage-based classification scheme forFrontiers in Oncology | www.frontiersin.org 6pituitary adenomas, in which TFs such as PIT-1, T-PIT, and SF-1
serve as key classifiers. Many groups have adopted this new
classification system and updated their guidelines for
pathological diagnosis of pituitary adenomas (8). There have
been several reports on early experiences with the new WHO
classification system (9, 10). Before adopting a new classification
system at our institution, we validated the reliability of antibodies
for three TFs: PIT-1, T-PIT, and SF-1.
We created a cohort in which (1) patients’ pituitary hormone
stains were all negative or singly positive and (2) their clinical
manifestation and endocrine laboratory tests were consistent
with the pituitary hormone stain results. In this 153-patient
cohort, tumor hormonal activity was clearly defined by serum
hormone levels and IHC for pituitary hormones. We then
performed TF stains and evaluated whether the results were
well matched to the previously established diagnosis. In this well-
refined cohort, the diagnoses based on the new WHO
classification were concordant with the original diagnosis.
There were only five cases with discordant results, including
three positive for SF-1 even though all negative hormonal stains
were the majority. Although there has been concern that reliable
commercial antibodies for T-PIT are not yet available (1), our T-
PIT antibody was successfully validated for its accuracy (94.7%).
Convinced by the successful retrospective validation results,
we changed our diagnostic protocol of pathological pituitary
adenoma examination (Figure 1). We first performed IHC for
three different TFs: PIT-1, T-PIT, and SF-1. After tumor cell
lineage was identified, IHC was only performed for the relevant
hormones. When the TF and pituitary hormone staining results
were discordant, IHC was carried out for the remaining pituitary
hormones. We experienced 3 cases with positive stains for
multiple TFs; 2 in acromegaly and 1 in Cushing’s disease. We
repeated IHC for both TFs and pituitary hormones and
confirmed the same results. Moreover, these unusual cases have
been reported by other groups (10–12). This should be further
investigated as current WHO classification system does not provide
how to classify theses unusual tumors. Recently, Neou et al.A B C
FIGURE 4 | Clinical characteristics of endocrine-inactive tumors. (A). Null cell adenomas and gonadotroph adenomas did not differ in size whereas silent PIT-1
adenomas were the smallest. (B, C). Null cell adenomas showed more frequent cavernous sinus invasion than gonadotroph adenomas, which makes total removal
loss feasible in patient with null cell adenomas. The incidence of cavernous sinus invasion was the highest in silent corticotroph adenoma. On the contrary, patients
with gonadotroph adenomas were less likely to have cavernous sinus invasion. Among 29 patients with silent PIT-1 adenomas, 28 patients underwent total removal,
which was significantly higher than patients with null cell adenomas or silent corticotroph adenomas. Cavernous sinus invasion was identified by preoperative
magnetic resonance imaging and based on surgeon’s inspection intraoperatively. PIT-1, pituitary specific transcription factor 1; *P < 0.05.September 2021 | Volume 11 | Article 739290
Hong et al. New WHO Classification for Pituitary Adenomasdemonstrated that unsupervised multi-panel genomic classification
of pituitary adenomas generally well correlates with cell lineage
classification, which is good agreement with the new WHO
classification scheme (13). For the cases with discrepancies
between TFs and pituitary hormones, transcriptome or
methylome analysis may help to clarify their identities.
While a guideline or consensus on the threshold of hormone-
positive tumor cells for immunohistochemical classification is
not available, it has been our strategy that only one positive,
unequivocally neoplastic cell is regarded as significant. In our
clinical practice, we have often experienced cases in which the
presence of single hormone-positive tumor cell was well matched
with clinical diagnosis. However, low threshold of positive stain
for pituitary hormones in our institution may possibly result in
different observations from the literature. Indeed, we have more
tumors with positive stains for two or more hormones than
single hormone-positive tumors in PIT-1 positive adenomas, and
low threshold of hormone-positivity may be the reason for
this observation.
In our earlier series (14) when TF stains were not available,
66.3% of clinically endocrine-inactive pituitary adenomas were
negative for any of pituitary hormone stains and thus classified as
null cell adenomas. In our current study, among 254 endocrine-
inactive tumors with no clinical or laboratory evidence of
hormonal excess, we identified 111 tumors (43.7%) true null cell
adenomas. Although the proportion of null cell adenomas were
much lowered, this is still much higher proportion compared with
other groups (1, 9, 15, 16). One of the possible explanation for the
discrepancies in the incidence of null cell adenomas is that
gonadotroph adenomas are possibly underdiagnosed in our
study although we validated the reliability of SF-1 antibody in
our retrospective investigation. Among 50 patients with pituitary
adenomas whose pathological examinations were discrepant
between transcription factor stains and pituitary hormone stains,
the majority of mismatched cases were gonadotroph adenomas
(43 patients, 86.0%) with stains positive for SF-1 but negative for
both FSH and LH. Considering the threshold of hormone-
positivity is very low in our study, we believe it should be
further validated whether single SF-1immunostain is sufficient to
characterize gonadotroph adenomas and whether current
antibody for SF-1 is a reliable. Further investigation with IHC
for GATA2, GATA3 and alpha subunit would help the
differentiation between true null cell adenomas and gonadotroph
adenomas and thus provide the true prevalence of null cell
adenomas (17–19). Unlike other endocrine-active adenomas,
most gonadotroph adenomas are clinically non-functioning
tumors that lack hormone overproduction. Although their cell
linages are apparently different, distinguishing between
gonadotroph and null cell adenomas has always been difficult.
Traditionally, null cell adenomas were considered a synonym of
pituitary hormone-negative pituitary adenomas; however, the new
WHO classification clearly defined null adenomas as tumors that
do not exhibit immunoreactivity for pituitary hormones or TFs.
Nishioka et al. demonstrated that up to 95% of pituitary adenomas
negative for any pituitary hormones actually expressed lineage-
specific TFs: SF-1 and/or estrogen receptor-a positive in 67%,Frontiers in Oncology | www.frontiersin.org 7T-PIT positive in 27% and PIT-1 positive in 2% (15). Thus, they
suggested only 5% of tumors were true null cell adenomas. This
observation was supported by Mete et al., who reported that
the incidence of null cell tumors in their series was only 4.5%
(20). We identified 111 null cell adenomas out of 158 adenomas
with negative stains for any pituitary hormones, suggesting
that its prevalence may be much higher than previously
reported (Table 3).
In the subgroup analysis on 254 clinically endocrine-inactive
tumors (Table 4), null cell adenomas were the majority, followed
by gonadotroph adenomas. We also observed more silent PIT-1
adenomas (n=29) than silent corticotroph adenomas (n=23),
which was different from a previous observation (15). We
compared these four subtypes of endocrine-inactive tumors in
terms of size, cavernous invasion probability, and likelihood of
total resection. Unsurprisingly, silent corticotroph adenomas
showed the highest incidence of cavernous sinus invasion and
the lowest possibility of complete tumor removal. Null cell
adenomas, gonadotroph adenomas, and silent corticotroph
adenomas were similar in size. Null cell adenomas were more
likely to invade the cavernous sinus compared with gonadotroph
adenomas. Consequently, total resection was less likely for null
cell adenomas. Although this finding should be further validated
with long-term follow-up (21), null adenomas seem to be
clinically more aggressive than gonadotroph adenomas,
suggesting that this discrimination may be critical for
patient management.CONCLUSION
The newWHO classification scheme is mostly well matched with
the traditional classification scheme. Gonadotroph adenomas
lacking FSH and LH stains account for the majority of
discrepancies in clinical settings, and further validation and
characterization of this small subset of pituitary adenomas may
be necessary. Null cell adenomas may be more prevalent than
previously reported, which requires further verification. Until the
new classification is further validated and interpreted with long-
term clinical outcomes, routine histological examination should
include a full slate of immunostains for both pituitary hormones
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